Dementia Associated With Alzheimer’s Disease is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Dementia Associated With Alzheimer’s Disease have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Dementia Associated With Alzheimer’s Disease compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dementia Associated With Alzheimer’s Disease overview
Alzheimer’s disease (AD) is the most common cause of dementia. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and changes in behavior and thinking skills that interfere with daily functioning. Early symptoms may include mild forgetfulness, difficulty recalling recent events or information, and trouble with problem-solving or complex tasks. One of the hallmark features of AD is the impairment of memory, particularly short-term memory. Individuals may have trouble remembering recent conversations, names, or important dates. As the disease progresses, individuals may experience changes in behavior, mood swings, confusion, disorientation, difficulty in following conversations, and problems with language (aphasia). They may also withdraw from social activities and exhibit changes in personality. Alzheimer’s disease is associated with the accumulation of abnormal protein deposits in the brain, including beta-amyloid plaques and tau tangles, which disrupt communication between brain cells, leading to their degeneration and death.
For a complete picture of PTSR and LoA scores for drugs in Dementia Associated With Alzheimer’s Disease, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
